A federal advisory panel voted on July 23, 2026 to recommend that compounding pharmacies in the United States be allowed to make four unapproved peptides: BPC-157, KPV, TB-500 and MOTS-c
Third-Party Verification : Each batch is tested by independent laboratories to confirm the absence of contaminants and verify the active compound concentration, providing transparent quality documentation through available certificates of analysis
O'LEARY, R.K., WATKINS, W.D., & GUESS, W.L
Bao L, et al
The quality control process for raw materials and finished products in carefully scrutinized with specifications and certificates of analysis verified annually
A novel peptide containing a nine acid sequences from Nur77 induces Bcl-2 dependent apoptosis in AML